Sugi Predict

Sugi Predict / Compounds / SCHEMBL160276

SCHEMBL160276

SCHEMBL160276

O=C(O)c1cc([N+](=O)[O-])n[nH]1

nearest known ligand 0.51

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ TP53 P04637 1/20 0.44
▸ ALPL P05186 10/20 0.42
▸ CA12 O43570 5/20 0.42
▸ RPA1 P27694 1/20 0.41
▸ HCAR3 P49019 4/20 0.40
▸ PIN1 Q13526 1/20 0.40
▸ CA9 Q16790 3/20 0.39
▸ HCAR2 Q8TDS4 1/20 0.39
▸ APEX1 P27695 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13387620 0.85 SMN1; SMN2 (0.44) SMN1; SMN2TP53ALPLCA12HCAR3
SCHEMBL27466968 0.84 TSHR (0.52) SMN1; SMN2TP53ALPLPIN1CA9
SCHEMBL175136 0.83 SMN1; SMN2 (0.40) SMN1; SMN2
SCHEMBL16524045 0.83 SMN1; SMN2 (0.37) SMN1; SMN2
SCHEMBL12332643 0.83 SMN1; SMN2 (0.37) SMN1; SMN2HCAR3
SCHEMBL627520 0.79 MAPK1 (0.57) SMN1; SMN2ALPL
SCHEMBL21964602 0.75 ALPL (0.47) ALPL
SCHEMBL17796561 0.75 MAPT (0.58) SMN1; SMN2TP53ALPL
SCHEMBL14917715 0.74 MAPK1 (0.34) SMN1; SMN2ALPL
SCHEMBL3932634 0.74 MAPK8 (0.55) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631560-A2 C-FMS KINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-03-08 — — EP claimed
US-20050004112-A1 C-fms kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2005-01-06 — — US claimed
WO-2004096795-A2 C-FMS KINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2004-11-11 — — WO claimed
EP-4743446-A1 NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA Board of Trustees of Michigan State University (US) 2026-05-20 — — EP disclosed
US-12570612-B2 Substituted nitrogen heterocyclic compound and anesthetic effect thereof CHENGDU MFS PHARMA. CO., LTD. (CN) 2026-03-10 — — US disclosed
WO-2025126109-A1 ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2025-06-19 — — WO disclosed
WO-2025119300-A1 MYT1 KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 广东东阳光药业股份有限公司 2025-06-12 — — WO disclosed
CN-120118088-A Myt1 kinase inhibitor compounds, pharmaceutical compositions thereof and uses thereof 广东东阳光药业股份有限公司 2025-06-10 — — CN disclosed
US-20250073218-A1 NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND UPPTHERA (KR) 2025-03-06 — — US disclosed
CN-119371411-A Phenyl fused ring compounds and their use in the central nervous system 乐普（北京）医疗器械股份有限公司 2025-01-28 — — CN disclosed
EP-4055019-B1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS INC (US) 2025-01-22 — — EP disclosed
US-20060111411-A1 Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents SCHERING CORPORATION 2006-05-25 — — US disclosed
EP-1631560-A2 C-FMS KINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-03-08 — — EP disclosed
US-20050239808-A1 Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH (DE) 2005-10-27 — — US disclosed
CN-1620296-A Substituted quinazoline derivatives as inhibitors of aurora kinases ASTRAZENECA AB (SE) 2005-05-25 — — CN disclosed
US-20050070561-A1 Substituted quinazoline derivatives as inhibitors of aurora kinases ASTRAZENECA AB (SE) 2005-03-31 — — US disclosed
US-20050004112-A1 C-fms kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2005-01-06 — — US disclosed
WO-2004096795-A2 C-FMS KINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2004-11-11 — — WO disclosed
EP-1463506-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES Astrazeneca AB (SE) 2004-10-06 — — EP disclosed
WO-2003055491-A1 SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES ASTRAZENECA AB (SE) 2003-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250073218-A1 NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND NLRP3, XIAP, NLRP1 SMN1; SMN2 4091/4885TP53 375/4885ALPL 4432/4885
US-20050239808-A1 Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur PRNP, APP, MAPT SMN1; SMN2 873/4885TP53 740/4885ALPL 4149/4885
US-20060111411-A1 Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents GTF3C5, RNGTT, GTF3C1 SMN1; SMN2 3977/4885TP53 2391/4885ALPL 4739/4885
US-20050070561-A1 Substituted quinazoline derivatives as inhibitors of aurora kinases AURKC, AURKA, AURKB SMN1; SMN2 4596/4885TP53 422/4885ALPL 2203/4885
US-12570612-B2 Substituted nitrogen heterocyclic compound and anesthetic effect thereof CNR1, SCN8A, KCNH1 SMN1; SMN2 1005/4885TP53 4712/4885ALPL 3202/4885
US-20050004112-A1 C-fms kinase inhibitors FLT3, FGR, FER SMN1; SMN2 4137/4885TP53 374/4885ALPL 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.